<i>Helicobacter pylori</i> infection: from standard to alternative treatment strategies

Sousa, Cláudia; Ferreira, R.; Azevedo, Nuno F.; Oleastro, Mónica; Azeredo, Joana; Figueiredo, Céu; Melo, Luís D. R.

doi:10.1080/1040841x.2021.1975643

Cited by 51 publications

(33 citation statements)

References 220 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, spontaneous induction of phages was also observed in other H. pylori strains [ 29 , 30 , 32 , 37 ], as well as induction of prophages after subsequent exposure to citrate–phosphate buffer at pH 6 and 3 [ 38 ]. To date, there have been no published reports on H. pylori prophages induced using Mitomycin C (reviewed in [ 12 ]).…”

Section: Discussionmentioning

confidence: 99%

“…The first-line therapeutic strategies recommend the selection of a treatment regimen based on previous antibiotic exposure or on the resistance rate of the region [ 9 ]. The decreasing eradication rate (80% to 90% in the 1990s and <70% in recent years), attributable to the increase in the occurrence of antibiotic-resistant strains [ 9 , 10 ], as well as a series of adverse effects promoted by antibiotics [ 11 ], have driven the search for alternative therapies or complementary approaches to tackle H. pylori infections [ 12 ]. In 2017, clarithromycin-resistant H. pylori was designated by the World Health Organization (WHO) as a high-priority microorganism for antibiotic research and development [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Characterization and Genomic Analysis of a New Phage Infecting Helicobacter pylori

Ferreira

Sousa

Gonçalves

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

Helicobacter pylori, a significant human gastric pathogen, has been demonstrating increased antibiotic resistance, causing difficulties in infection treatment. It is therefore important to develop alternatives or complementary approaches to antibiotics to tackle H. pylori infections, and (bacterio)phages have proven to be effective antibacterial agents. In this work, prophage isolation was attempted using H. pylori strains and UV radiation. One phage was isolated and further characterized to assess potential phage-inspired therapeutic alternatives to H. pylori infections. HPy1R is a new podovirus prophage with a genome length of 31,162 bp, 37.1% GC, encoding 36 predicted proteins, of which 17 were identified as structural. Phage particles remained stable at 37 °C, from pH 3 to 11, for 24 h in standard assays. Moreover, when submitted to an in vitro gastric digestion model, only a small decrease was observed in the gastric phase, suggesting that it is adapted to the gastric tract environment. Together with its other characteristics, its capability to suppress H. pylori population levels for up to 24 h post-infection at multiplicities of infection of 0.01, 0.1, and 1 suggests that this newly isolated phage is a potential candidate for phage therapy in the absence of strictly lytic phages.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Characterization and Genomic Analysis of a New Phage Infecting Helicobacter pylori

Ferreira

Sousa

Gonçalves

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Finally, vaccination is an attractive strategy for combatting Hp infection globally. Various attempts have been made to develop an Hp vaccine over the years, but the results have been disappointing [ 166 ]. Whereas some vaccine candidates have shown potential as an option for prophylaxis, none have yet shown a therapeutic effect [ 166 , 167 ].…”

Section: Recent Advancesmentioning

confidence: 99%

Current and Future Perspectives in the Diagnosis and Management of Helicobacter pylori Infection

Shatila

Thomas

2022

JCM

View full text Add to dashboard Cite

Helicobacter pylori (Hp) is a prevalent organism infecting almost half the global population. It is a significant concern, given its associated risk of gastric cancer, which is the third leading cause of cancer death globally. Infection can be asymptomatic or present with dyspeptic symptoms. It may also present with alarm symptoms in the case of progression to cancer. Diagnosis can be achieved non-invasively (breath tests, stool studies, or serology) or invasively (rapid urease test, biopsy, or culture). Treatment involves acid suppression and regimens containing several antibiotics and is guided by resistance rates. Eradication is essential, as it lowers the risk of complications and progression to cancer. Follow-up after eradication is similarly important, as the risk of cancer progression remains. There have been many recent advances in both diagnosis and treatment of Hp. In particular, biosensors may be effective diagnostic tools, and nanotechnology, vaccines, and potassium-competitive acid blockers may prove effective in enhancing eradication rates.

show abstract

“…Moreover, according to the World Health Organization (WHO), stomach cancer associated with H. pylori caused up to 0.5 million deaths in the world population ( Arora et al, 2012 ). There are several comprehensive reviews which have discussed the pathogenesis and pharmacotherapy of H. pylori infection ( Georgopoulos and Papastergiou, 2020 ; Alexander et al, 2021 ; Tshibangu-Kabamba and Yamaoka, 2021 ; Ansari and Yamaoka, 2022 ; Sousa et al, 2022 ). To our knowledge, there has been little attention paid to the potential use of antibiotics and other antimicrobial agents in terms of the biopharmaceutical implications.…”

Section: Introductionmentioning

confidence: 99%

The Potential Use of Antibiotics Against Helicobacter pylori Infection: Biopharmaceutical Implications

et al. 2022

View full text Add to dashboard Cite

Helicobacter pylori (H. pylori) is a notorious, recalcitrant and silent germ, which can cause a variety of debilitating stomach diseases, including gastric and duodenal ulcers and gastric cancer. This microbe predominantly colonizes the mucosal layer of the human stomach and survives in the inhospitable gastric microenvironment, by adapting to this hostile milieu. In this review, we first discuss H. pylori colonization and invasion. Thereafter, we provide a survey of current curative options based on polypharmacy, looking at pharmacokinetics, pharmacodynamics and pharmaceutical microbiology concepts, in the battle against H. pylori infection.

show abstract

Helicobacter pylori infection: from standard to alternative treatment strategies

Cited by 51 publications

References 220 publications

Characterization and Genomic Analysis of a New Phage Infecting Helicobacter pylori

Characterization and Genomic Analysis of a New Phage Infecting Helicobacter pylori

Current and Future Perspectives in the Diagnosis and Management of Helicobacter pylori Infection

The Potential Use of Antibiotics Against Helicobacter pylori Infection: Biopharmaceutical Implications

Contact Info

Product

Resources

About